Abbott Laboratories Stock Forecast for 2023 - 2025 - 2030
Updated on 12/06/2023
Abbott Laboratories Stock Forecast and Price Target
Abbott Laboratories's stock price reaches the average target of $115.30 by 2024 as expected recently by fiveteen notable experts, there would be a potential upside of approximately 9.87% from the last closing price in December, 2023. This possible increase is based on a high estimate of $133.00 and a low estimate of $100.00. If you are interested in ABT stock, it is important to also consider its competitors.
9.87% Upside
Abbott Laboratories Fair Value Forecast for 2023 - 2025 - 2030
In the last three years, Abbott Laboratories's Price has grown by 64.81%, rising from $80.84 to $133.23. For the following year, the 22 analysts predict that Abbott Laboratories's Fair Value will drop by 6.37%, reaching $124.75. Over the next eight years, experts predict that Abbott Laboratories's Fair Value will grow at a rate of 25.82%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ISRG Stock Forecast | Intuitive Surgical Inc | Outperform |
15
|
$310.26 | Buy/Sell | $360.83 | 3.95% |
| BSX Stock Forecast | Boston Scientific Corp | Outperform |
11
|
$54.82 | Buy/Sell | $60.80 | 9.45% |
| DXCM Stock Forecast | DexCom Inc | Buy |
16
|
$117.94 | Buy/Sell | $125.98 | 5.99% |
| RMD Stock Forecast | ResMed Inc | Outperform |
17
|
$164.00 | Buy/Sell | $220.76 | 6.10% |
| VAR Stock Forecast | Varian Medical Systems | - |
16
|
$176.53 | Buy/Sell | $177.67 | -100.00% |
Abbott Laboratories Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Abbott Laboratories's Revenue has grown by 36.83%, rising from $31.90B to $43.65B. For the following year, the 23 analysts predict that Abbott Laboratories's Revenue will drop by 5.19%, reaching $41.39B. Over the next eight years, experts predict that Abbott Laboratories's Revenue will grow at a rate of 17.32%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| PODD Stock Forecast | Insulet | Outperform |
15
|
$189.30 | Buy/Sell | $222.05 | 22.56% |
| LVGO Stock Forecast | Livongo Health | - |
0
|
$0.00 | Buy/Sell | $0.00 | 0.00% |
| SWAV Stock Forecast | Shockwave Medical | Outperform |
4
|
$172.53 | Buy/Sell | $0.00 | 36.79% |
.jpg)
Abbott Laboratories Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, Abbott Laboratories's Dividend per Share has grown, rising from $1.32 to $1.92 – a growth of 45.45%. In the next year, analysts believe that Dividend per Share will reach $1.96 – an increase of 2.08%. For the next eight years, the forecast is for Dividend per Share to grow by 32.24%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MASI Stock Forecast | Masimo | Outperform |
14
|
$103.62 | Buy/Sell | $92.00 | -17.00% |
| INSP Stock Forecast | Inspire Medical Systems | Outperform |
6
|
$151.74 | Buy/Sell | $0.00 | 41.69% |
| CMD Stock Forecast | Cantel Medical LLC | - |
17
|
$0.05 | Buy/Sell | $85.00 | -100.00% |
Abbott Laboratories Free Cash Flow Forecast for 2023 - 2025 - 2030
Abbott Laboratories's Free Cash Flow has seen impressive growth In the last three years, rising from $4.50B to $7.70B – a growth of 71.10%. In the next year, analysts believe that Free Cash Flow will reach $8.56B – an increase of 11.26%. For the next eight years, the forecast is for Free Cash Flow to grow by 42.51%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CNMD Stock Forecast | CONMED | Outperform |
16
|
$108.35 | Buy/Sell | $123.38 | 13.06% |
| ITGR Stock Forecast | Integer Holdings | Outperform |
16
|
$86.50 | Buy/Sell | $95.00 | 4.05% |
| AXNX Stock Forecast | Axonics | Outperform |
7
|
$57.35 | Buy/Sell | $0.00 | 20.31% |
Abbott Laboratories Net Income Forecast for 2023 - 2025 - 2030
Abbott Laboratories's Net Income has grown In the last three years, rising from $3.69B to $6.93B – a growth of 88.04%. In the next year, analysts believe that Net Income will reach $8.79B – an increase of 26.80%. For the next eight years, experts predict that Abbott Laboratories's Net Income will grow at a rate of 68.68%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| IRTC Stock Forecast | iRhythm Technologies | Outperform |
11
|
$84.95 | Buy/Sell | $0.00 | 28.90% |
| TMDX Stock Forecast | TransMedics Group | Buy |
8
|
$73.94 | Buy/Sell | $0.00 | 8.20% |
| GNMK Stock Forecast | GenMark Diagnostics | - |
2
|
$0.00 | Buy/Sell | $24.05 | 0.00% |
Abbott Laboratories EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Abbott Laboratories's EBITDA has grown by 55.75%, rising from $7.77B to $12.10B. For the next year, 11 analysts project Abbott Laboratories's EBITDA to drop by 1.35%, reaching $11.94B. Over the next eight years, experts believe that Abbott Laboratories's EBITDA will grow at a rate of 7.17%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| TNDM Stock Forecast | Tandem Diabetes Care | Outperform |
9
|
$22.23 | Buy/Sell | $28.33 | -1.03% |
| NTUS Stock Forecast | Natus Medical | - |
14
|
$32.96 | Buy/Sell | $36.00 | -100.00% |
| QTRX Stock Forecast | Quanterix | Outperform |
11
|
$23.20 | Buy/Sell | $38.25 | 44.40% |
Abbott Laboratories EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Abbott Laboratories's EBIT has grown, moving from $4.76B to $8.84B – an increase of 85.75%. In the next year, analysts predict that EBIT will jump to $10.32B – up 16.79% from the current level. Looking ahead to eight years, experts forecast that EBIT will grow by 52.67%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SLNO Stock Forecast | Soleno Therapeutics | Buy |
0
|
$34.06 | Buy/Sell | $6.00 | 23.31% |
| NVRO Stock Forecast | Nevro | Hold |
6
|
$18.92 | Buy/Sell | $20.09 | -10.15% |
| SOLY Stock Forecast | Soliton | - |
4
|
$22.59 | Buy/Sell | $23.00 | 6.33% |
Abbott Laboratories EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last three years, Abbott Laboratories's EPS has grown by 64.81%, rising from $3.24 to $5.34. For the following year, the 22 analysts predict that Abbott Laboratories's EPS will drop by 6.37%, reaching $5.00. Over the next eight years, experts predict that Abbott Laboratories's EPS will grow at a rate of 25.82%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CLPT Stock Forecast | ClearPoint Neuro | Buy |
11
|
$6.58 | Buy/Sell | $0.00 | 51.98% |
| PLSE Stock Forecast | Pulse Biosciences | - |
0
|
$9.01 | Buy/Sell | $37.00 | -100.00% |
| SILK Stock Forecast | Silk Road Medical, Inc | Hold |
7
|
$9.64 | Buy/Sell | $0.00 | 8.92% |
Site Navigation
.jpg)